These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34846878)

  • 21. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer.
    Frik M; Martínez A; Elie BT; Gonzalo O; Ramírez de Mingo D; Sanaú M; Sánchez-Delgado R; Sadhukha T; Prabha S; Ramos JW; Marzo I; Contel M
    J Med Chem; 2014 Dec; 57(23):9995-10012. PubMed ID: 25409416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
    Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
    J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondria-targeted ruthenium complexes can be generated in vitro and in living cells to target triple-negative breast cancer cells by autophagy inhibition.
    Zhang GD; Wang MM; Su Y; Fang H; Xue XL; Liu HK; Su Z
    J Inorg Biochem; 2024 Jul; 256():112574. PubMed ID: 38677004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
    Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
    Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
    PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, Characterization, and Cytotoxicity of Morpholine-Containing Ruthenium(II)
    Chatterjee R; Bhattacharya I; Roy S; Purkait K; Koley TS; Gupta A; Mukherjee A
    Inorg Chem; 2021 Aug; 60(16):12172-12185. PubMed ID: 34346215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA targeting half sandwich Ru(II)-
    Mondal A; Sen U; Roy N; Muthukumar V; Sahoo SK; Bose B; Paira P
    Dalton Trans; 2021 Jan; 50(3):979-997. PubMed ID: 33355328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxicity of Ru(II) piano-stool complexes with chloroquine and chelating ligands against breast and lung tumor cells: Interactions with DNA and BSA.
    Colina-Vegas L; Villarreal W; Navarro M; de Oliveira CR; Graminha AE; Maia PIDS; Deflon VM; Ferreira AG; Cominetti MR; Batista AA
    J Inorg Biochem; 2015 Dec; 153():150-161. PubMed ID: 26277415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
    Chakraborty A; Roy S; Chakraborty MP; Roy SS; Purkait K; Koley TS; Das R; Acharya M; Mukherjee A
    Inorg Chem; 2021 Dec; 60(23):18379-18394. PubMed ID: 34780170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A photoactivatable Ru (II) complex bearing 2,9-diphenyl-1,10-phenanthroline: A potent chemotherapeutic drug inducing apoptosis in triple negative human breast adenocarcinoma cells.
    Mansour N; Bodman-Smith K; Khnayzer RS; Daher CF
    Chem Biol Interact; 2021 Feb; 336():109317. PubMed ID: 33197429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer.
    Oliveira KM; Peterson EJ; Carroccia MC; Cominetti MR; Deflon VM; Farrell NP; Batista AA; Correa RS
    Dalton Trans; 2020 Nov; 49(45):16193-16203. PubMed ID: 32329497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arene Ruthenium(II) Complexes Bearing the κ-
    Arlt S; Petković V; Ludwig G; Eichhorn T; Lang H; Rüffer T; Mijatović S; Maksimović-Ivanić D; Kaluđerović GN
    Molecules; 2021 Mar; 26(7):. PubMed ID: 33806101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coumarin-modified ruthenium complexes: Synthesis, characterization, and antiproliferative activity against human cancer cells.
    Jakopec S; Hamzic LF; Bočkor L; Car I; Perić B; Kirin SI; Sedić M; Raić-Malić S
    Arch Pharm (Weinheim); 2024 Sep; 357(9):e2400271. PubMed ID: 38864840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.
    Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN
    Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New organometallic ruthenium(ii) complexes with purine analogs - a wide perspective on their biological application.
    Fandzloch M; Jędrzejewski T; Dobrzańska L; Esteban-Parra GM; Wiśniewska J; Paneth A; Paneth P; Sitkowski J
    Dalton Trans; 2021 Apr; 50(16):5557-5573. PubMed ID: 33908935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lapachol in the Design of a New Ruthenium(II)-Diphosphine Complex as a Promising Anticancer Metallodrug.
    Oliveira KM; Honorato J; Demidoff FC; Schultz MS; Netto CD; Cominetti MR; Correa RS; Batista AA
    J Inorg Biochem; 2021 Jan; 214():111289. PubMed ID: 33137682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GSH-resistant and highly cytoselective ruthenium(II)-
    Kar B; Das U; De S; Pete S; Sharma S A; Roy N; S K AK; Panda D; Paira P
    Dalton Trans; 2021 Aug; 50(30):10369-10373. PubMed ID: 34308466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imine-N-Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p-Cymene Anticancer Complexes: A Structure-Activity Relationship Study.
    Yang Y; Guo L; Tian Z; Liu X; Gong Y; Zheng H; Ge X; Liu Z
    Chem Asian J; 2018 Oct; 13(19):2923-2933. PubMed ID: 30101417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells.
    Montani M; Pazmay GVB; Hysi A; Lupidi G; Pettinari R; Gambini V; Tilio M; Marchetti F; Pettinari C; Ferraro S; Iezzi M; Marchini C; Amici A
    Pharmacol Res; 2016 May; 107():282-290. PubMed ID: 27038531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.